Report on prostate cancer

• Date :
• 19    
  0

TITAN trial

• Date :
• 4    
  0

AXL inhibitor bemcentinib in combination with chemotherapy exerts anti-leukaemic activity

• Date :
• 4    
  0

Using large scale data will help provide more breakthroughs

• Date :
• 3    
  0

ARCHES trial

• Date :
• 2    
  0

Report on pancreatobiliary cancers

• Date :
• 2    
  0

ABC-06 trial results: Second-line ASC+mFOLFOX chemotherapy for suitable patients

• Date :
• 2    
  0

No difference in survival between laparoscopic surgery and open surgery

• Date :
• 2    
  0

Enzalutamide as treatment for men with mHSPC who have received testosterone suppression

• Date :
• 2    
  0

DUTRENEO Trial

• Date :
• 1    
  0

POLO III trial for metastatic pancreatic cancer

• Date :
• 1    
  0

Using olaparib alone or with durvalumab

• Date :
• 1    
  0

Important results as other cancer areas

• Date :
• 1    
  0

FORTE trial results: KRd with or without transplantation in newly diagnosed myeloma

• Date :
• 1    
  0

POLO Trial: Olaparib as a maintenance treatment following first-line

• Date :
• 1    
  0

Proton therapy or photon therapy as part of concurrent chemoradiotherapy

• Date :
• 1    
  0

Olaparib and durvalumab in metastatic BRCA wild type triple-negative breast cancer

• Date :
• 1    
  0

Challenges in global cancer control

• Date :
• 1    
  0

ENZAMET trial

• Date :
• 0    
  0

FIERCE study

• Date :
• 0    
  0

ARAMIS trial

• Date :
• 0    
  0

Report on breast cancer

• Date :
• 0    
  0

Report on CNS malignancies

• Date :
• 0    
  0

Report on sarcomas

• Date :
• 0    
  0

Highlights from ASCO 2019

• Date :
• 0    
  0

Modular phase I/II clinical trial evaluating the selective MET-kinase inhibitor OMO-1

• Date :
• 0    
  0

Breast cancer highlights from ASCO 2019

• Date :
• 0    
  0

VOLFI trial final results: mFOLFOXIRI and panitumumab versus FOLFOXIRI

• Date :
• 0    
  0

Advances in PARP inhibitor use for metastatic breast cancer

• Date :
• 0    
  0

Metastatic castration resistant prostate cancer

• Date :
• 0    
  0

Prostate cancer updates: TITAN and ENZAMET

• Date :
• 0    
  0

Novel therapies in the treatment of bladder cancer

• Date :
• 0    
  0

Metastatic bladder cancer: Current practice and latest data

• Date :
• 0    
  0

Clinical updates for metastatic hormone sensitive prostate cancer

• Date :
• 0    
  0

Chemotherapy for frail and elderly patients with advanced gastroesophageal cancer

• Date :
• 0    
  0

Laparoscopic versus open resection for colorectal liver metastases

• Date :
• 0    
  0

Updated data from MSI high metastatic colon cancer patients

• Date :
• 0    
  0

Should we give everything to patients with unresectable locally advanced

• Date :
• 0    
  0

Comparing gemcitabine and cisplatin with bevacizumab to placebo

• Date :
• 0    
  0

Maintenance pembrolizumab vs placebo for metastatic urothelial cancer

• Date :
• 0    
  0

Margetuximab and chemo versus trastuzumab and chemo in HER2 positive MBC

• Date :
• 0    
  0

Alpelisib and endocrine therapy in patients with PIK3CA-mutated/HR

• Date :
• 0    
  0

A study of co-expression extrapolation (COXEN) with neoadjuvant chemotherapy

• Date :
• 0    
  0

Cutting-edge cancer care at the Miami Cancer Institute

• Date :
• 0    
  0

Implementing better cancer diagnosis in low and middle income countries

• Date :
• 0    
  0

Understanding eligibility criteria for clinical trials

• Date :
• 0    
  0

New agent targeting Nectin-4 produces responses in nearly half

• Date :
• 0    
  0

Enfortumab vedotin is an effective therapy and important development

• Date :
• 0    
  0

Expanded clinical trial inclusion criteria would double the percentage

• Date :
• 0    
  0

Preliminary results of earlier steroid use with axicabtagene ciloleucel in patients

• Date :
• 0    
  0

Evaluation of AMG 420, an anti-BCMA bispecific T-cell engager (BiTE)

• Date :
• 0    
  0

EMBRACA: Results of talazoparib vs chemotherapy

• Date :
• 0    
  0

Carfilzomib and irinotecan in relapsed small cell lung cancer

• Date :
• 0    
  0

Weekly 20/56 mg/m² carfilzomib, lenalidomide and dexamethasone until progression

• Date :
• 0    
  0

Maintenance with weekly carfilzomib in elderly newly diagnosed multiple myeloma

• Date :
• 0    
  0

Margetuximab for the treatment of HER2-positive breast cancer

• Date :
• 0    
  0

The future of PARP inhibitors in metastatic breast cancer

• Date :
• 0    
  0

Ribociclib plus endocrine therapy improves survival in premenopausal patients

• Date :
• 0    
  0

Surveying cancer patients' mental health and financial problems

• Date :
• 0    
  0

Long-term survival after laparoscopic versus open resection for colorectal liver metastases

• Date :
• 0    
  0

Formas de control y prevención de cáncer en Latinoamérica

• Date :
• 0    
  0

Cancer care in Latin America

• Date :
• 0    
  0

Expanding clinical trial eligibility criteria: Risks and solutions

• Date :
• 0    
  0

Pembrolizumab increases long-term survival in patients with advanced NSCLC

• Date :
• 0    
  0

A study of KTE-C19 in adults with relapsed/refractory acute lymphoblastic leukaemia

• Date :
• 0    
  0

Novel methods of drug testing and biopsy in India

• Date :
• 0    
  0

Cancer care in low and middle income countries

• Date :
• 0    
  0

Improving access to quality palliative care

• Date :
• 0    
  0

Fighting cancer through increasing awareness, screening, advocacy

• Date :
• 0    
  0

PARP inhibitor olaparib as treatment for pancreatic cancer patients with BRCA gene mutations

• Date :
• 0    
  0

Anti-tumour activity of TAK-788 in NSCLC patients with EGFR exon 20 insertions

• Date :
• 0    
  0

It is essential to identify the BRCA gene

• Date :
• 0    
  0

Maintenance therapy with PARP inhibitor olaparib delays progression in patients with BRCA

• Date :
• 0    
  0

Using enzalutamide will allow patients to avoid chemotherapy

• Date :
• 0    
  0

Enzalutamide improves survival for men with metastatic hormone-sensitive prostate cancer

• Date :
• 0    
  0

Clinical and translational results from the NEOSTAR study

• Date :
• 0    
  0

Resultados de estudio fase 2. Combinación pembrolizumab y el inhibidor AXL.

• Date :
• 0    
  0

A phase II study of bemcentinib with pembrolizumab in patients with advanced NSCLC

• Date :
• 0    
  0

Implementing the Breast Health Global Initiative guidelines

• Date :
• 0    
  0

Ado-trastuzumab emansine in patients with HER2 amplified salivary gland cancers

• Date :
• 0    
  0

Mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2

• Date :
• 0    
  0

Guiding treatment decisions through the use of molecular profiling in breast cancer

• Date :
• 0    
  0

Managing metastatic breast cancer and beyond using PARP inhibitors

• Date :
• 0    
  0

Updates in metastatic and early-stage breast cancer

• Date :
• 0    
  0

Targeting agent enfortumab vedotin a novel treatment

• Date :
• 0    
  0

Preventing brain metastases in patients with HER2+ or triple negative breast cancer

• Date :
• 0    
  0

The potential of PARP inhibitors for metastatic cancer

• Date :
• 0    
  0

CASSIOPEIA initial results

• Date :
• 0    
  0

PARP inhibitors in metastatic breast cancer: Where are we now?

• Date :
• 0    
  0

Adjuvant personalised therapy comparing endocrine therapy plus ribociclib

• Date :
• 0    
  0

Clinical activity and tolerability of the RET inhibitor BLUE-667 in patients

• Date :
• 0    
  0

Combination of olaratumab and doxorubicin versus doxorubicin alone

• Date :
• 0    
  0

PARP inhibitors are a promising alternative to chemotherapy

• Date :
• 0    
  0

Results from phase III trial looking at ribociclib as an addition

• Date :
• 0    
  0

Biomarker analysis from JAVELIN Renal 101

• Date :
• 0    
  0

Cytoreductive nephrectomy in metastatic renal cancer

• Date :
• 0    
  0

Subcutaneous versus intravenous daratumumab administration in patients with relapsed

• Date :
• 0    
  0

Improving cancer care outcomes in Ghana through mentorship

• Date :
• 0    
  0

Five year data from the phase Ib trial studying pembrolizumab

• Date :
• 0    
  0

Pembrolizumab as treatment for advanced gastroesophageal junction

• Date :
• 0    
  0

Comment: Reasonable to conclude that pembrolizumab is non-inferior to chemotherapy

• Date :
• 0    
  0

Pembrolizumab comparable to chemotherapy for patients with advanced gastric

• Date :
• 0    
  0

The success of immunotherapy means we have to change our mindset as we treat patients

• Date :
• 0    
  0

Pembrolizumab is safe and effective and substantially increases overall survival in aNSCLC patients

• Date :
• 0    
  0

The use of CDK 4/6 inhibitors now translates to a significant survival benefit

• Date :
• 0    
  0

Ribociclib and endocrine therapy improves survival for pre-menopausal women

• Date :
• 0    
  0

44e Réunion Interdisciplinaire de Chimiothérapie Anti-Infectieuse

• Date :
• 4192    
  0

14èmes Journées des Référentiels en Soins Oncologiques de support - AFSOS 2024

• Date :
• 3855    
  0

Post ASCO-ESMO 2024 Fédération Francophone de Cancérologie Digestive

• Date :
• 3190    
  0

45emes Journées de la Société Française de Sénologie et de Pathologie Mammaire - SFSPM 2024

• Date :
• 6936    
  0

Molecular Analysis for Precision Oncology Congress - MAP 2024

• Date :
• 2510    
  0